# A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects

Study · id `cardio:ct-nct01301066` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01301066](<https://clinicaltrials.gov/study/NCT01301066>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01301066

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 252 participants.

## Technical summary

Registry record NCT01301066. Randomized; double masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2013-03 (actual). Results posted on 2014-04-29.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 252 participants (enrolled count; ClinicalTrials.gov record NCT01301066, source copy `cardio:ctgov-nct01301066-2014-04-29`, retrieved 2026-10-31)
- Start date: 2010-12 (registry gives no type) (ClinicalTrials.gov record NCT01301066, source copy `cardio:ctgov-nct01301066-2014-04-29`, retrieved 2026-10-31)
- Primary completion: 2013-03 (actual) (ClinicalTrials.gov record NCT01301066, source copy `cardio:ctgov-nct01301066-2014-04-29`, retrieved 2026-10-31)
- Completion: 2013-03 (actual) (ClinicalTrials.gov record NCT01301066, source copy `cardio:ctgov-nct01301066-2014-04-29`, retrieved 2026-10-31)
- Results first posted: 2014-04-29 (ClinicalTrials.gov record NCT01301066, source copy `cardio:ctgov-nct01301066-2014-04-29`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01301066, source copy `cardio:ctgov-nct01301066-2014-04-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01301066-2014-04-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects
- Condition: Dyslipidemia
- Intervention (Drug): Pitavastatin
- Intervention (Drug): Pravastatin
- Lead sponsor: Kowa Research Institute, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Kowa Pharmaceuticals America, Inc.
- Collaborator class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record: Pitavastatin (`cardio:pitavastatin`)
- Registry intervention name matches this record: Pravastatin (`cardio:pravastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: Kowa Research Institute, Inc. (`cardio:org-kowa-research-institute-inc`)
- Registry lists this organization as a collaborator: Kowa Pharmaceuticals America, Inc. (`cardio:org-kowa-pharmaceuticals-america-inc`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV (`cardio:pubmed-28252528`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients (`cardio:pubmed-28121706`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial (`cardio:pubmed-28416195`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0fee5f386b00305b7c2daa3b3888ed7170d3e4ce52a1c25066e02e51caec95e7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
